Business
Ocumetics Announces Transition of Chief Medical Officer Consulting Role
(TheNewswire)   Calgary, Alberta – TheNewswire - January 9, 2026 - Ocumetic...
About this update from Ocumetics Technology Corp
[{"type":"text","content":"Ocumetics Announces Transition of Chief Medical Officer Consulting Role\n(TheNewswire)\n\n\n\n \n\n\nCalgary, Alberta – TheNewswire - January 9, 2026 -\nOcumetics Technology Corp. (“Ocumetics” or the “Company”)\n(TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation\nophthalmic technology, today announced that it\nintends to form a Scientific Advisory Committee (SAC) to fill the role\nnow being performed by a single Chief Medical Officer.  In the\nresult, the consulting agreement with the Corporation’s current\nChief Medical Officer, Dr. Doyle Stulting, will terminate following a\nninety-day transition period.\n\n\nAs Ocumetics advances toward completion of its\nFirst-in-Human (FIH) study and prepares for a pivotal FDA clinical\ntrial anticipated in 2027, the Company is evolving its medical and\nclinical leadership structure to align with its next exciting phase of\ngrowth and execution. The transition is from a single CMO structure to\na broader multi-member Scientific Advisory Committee (SAC) structure.\nThis committee will provide deeper and more diverse medical, clinical,\nand regulatory oversight as the Company advances toward late-stage\nclinical development.\n\n\nIt is intended that the SAC will be composed of\ninternationally recognized experts in ophthalmology, medical research,\nand lens science, allowing the Company to leverage broader expertise\nacross multiple disciplines critical to a successful pivotal trial and\ncommercialization pathway.\n\n\nThe Company will announce members of the Scientific\nAdvisory Committee in the coming months.  Ocumetics remains focused\non advancing its accommodating intraocular lens technology and\nexecuting its clinical and regulatory strategy to deliver excellent\ninnovative solutions for patients worldwide.\n\n\nDr. Stulting has played an important role in\nOcumetics’ development, contributing decades of clinical expertise,\nresearch insight, and leadership to the Company’s scientific and\nclinical programs.\n\n\n“Dr. Stulting’s resume and career speak for\nthemselves,” said Dean Burns, President and CEO of Ocumetics. “His\ncontributions to ophthalmology and to Ocumetics have been meaningful,\nand we sincerely appreciate the experience, perspective, and\ncommitment he brou...